Click here to view the Humana Medical Policy Updates Updates » September 2024 Humana Medical…
Humana December 2017 Pharmacy Policy Updates
Click here to view the Humana Pharmacy Policy Updates »
December 2017 Pharmacy Policy Updates
| Policy Name | Reviewed Date |
| Naftin® Gel (naftifine) | 12/28/2017 |
| Hemlibra® (emicizumab-kxwh) | 12/21/2017 |
| GLP-1 Analogs | 12/14/2017 |
| GLP-1 Analogs | 12/14/2017 |
| Nuedexta® (dextromethorphan and quinidine) | 12/14/2017 |
| Nuedexta® (dextromethorphan and quinidine) | 12/14/2017 |
| Opioid Utilization Program – Morphine equivalent dose (MED) edits | 12/14/2017 |
| Opioid Utilization Program – Morphine equivalent dose (MED) edits | 12/14/2017 |
| Afrezza® (insulin human) Inhalation Powder | 12/13/2017 |
| Aliqopa™ (copanlisib) | 12/13/2017 |
| Alpha-1 Proteinase Inhibitors (Aralast NP®, Glassia®) | 12/13/2017 |
| Alpha-1 Proteinase Inhibitors (Prolastin-C®, Zemaira®) | 12/13/2017 |
| Anzemet® (dolasetron) | 12/13/2017 |
| Arcalyst® (rilonacept) | 12/13/2017 |
| Atgam® (antithymocyte immune globulin, equine) | 12/13/2017 |
| Auvi-Q® (epinephrine injection) | 12/13/2017 |
| Azopt® (brinzolamide ophthalmic suspension) 1% | 12/13/2017 |
| Biguanide Agents | 12/13/2017 |
| Cayston® (aztreonam inhalation solution) | 12/13/2017 |
| Cytogam® (cytomegalovirus immune globulin, human) | 12/13/2017 |
| Darzalex® (daratumumab) | 12/13/2017 |
| Fusilev® (levoleucovorin) | 12/13/2017 |
| Fycompa® (perampanel) | 12/13/2017 |
| Gocovri™ (amantadine) | 12/13/2017 |
| High Risk Medications (HRM) in the Elderly | 12/13/2017 |
| Idiopathic Pulmonary Fibrosis Products (Ofev, Esbriet) | 12/13/2017 |
| Ilaris® (canakinumab) | 12/13/2017 |
| Iluvien® (fluocinolone acetonide intravitreal implant) | 12/13/2017 |
| Intron A® (interferon alfa-2b) | 12/13/2017 |
| Istodax® (romidepsin) | 12/13/2017 |
| Jakafi® (ruxolitinib) | 12/13/2017 |
| Lartruvo™ (olaratumab) | 12/13/2017 |
| Minocycline Extended Release | 12/13/2017 |
| Movantik® (naloxegol) | 12/13/2017 |
| Namenda® (memantine HCl) and Namenda XR® (memantine HCl extended-release) | 12/13/2017 |
| Nplate® (romiplostim) | 12/13/2017 |
| Oral Acne Antibiotics | 12/13/2017 |
| Osphena® (ospemifene) | 12/13/2017 |
| Otrexup ™ (methotrexate injection) | 12/13/2017 |
| Pomalyst® (pomalidomide) | 12/13/2017 |
| Prestalia® (perindopril-amlodipine) | 12/13/2017 |
| Promacta® (eltrombopag) | 12/13/2017 |
| Rapid-Acting Fentanyl (Abstral®, Actiq®, Fentora®, Lazanda®, Subsys®) | 12/13/2017 |
| Rayaldee® (calcifediol) | 12/13/2017 |
| Sandostatin® S.C., Sandostatin LAR® Depot (octreotide acetate for injection) | 12/13/2017 |
| Sandostatin® S.C., Sandostatin LAR® Depot (octreotide acetate for injection) | 12/13/2017 |
| Savaysa® (edoxaban) | 12/13/2017 |
| Sernivo™ (betamethasone dipropionate) Spray | 12/13/2017 |
| Sernivo™ (betamethasone dipropionate) Spray | 12/13/2017 |
| Signifor® LAR (pasireotide) | 12/13/2017 |
| Simbrinza™ (brinzolamide/brimonidine ophthalmic suspension) | 12/13/2017 |
| Simponi® (golimumab) | 12/13/2017 |
| Simponi® (golimumab) | 12/13/2017 |
| Soliqua™ 100/33 (insulin glargine and lixisenatide) | 12/13/2017 |
| Soliris® (eculizumab) | 12/13/2017 |
| Somatuline Depot® (lanreotide) | 12/13/2017 |
| Somavert® (pegvisomant) | 12/13/2017 |
| Soolantra® (ivermectin 1% topical cream) | 12/13/2017 |
| Supprelin® LA (histrelin acetate implant) | 12/13/2017 |
| Supprelin® LA (histrelin acetate implant) | 12/13/2017 |
| Symproic® (naldemedine) | 12/13/2017 |
| Taclonex® (calcipotriene and betamethasone dipropionate) | 12/13/2017 |
| Thymoglobulin® (anti-thymocyte globulin [rabbit]) | 12/13/2017 |
| Topical Rosacea Products | 12/13/2017 |
| Topical Tretinoin Containing Products | 12/13/2017 |
| Tracleer (bosentan) tablet for oral suspension | 12/13/2017 |
| Trelegy Ellipta® (fluticasone furoate, umeclidinium, vilanterol) | 12/13/2017 |
| Trulance™(plecanatide) | 12/13/2017 |
| Uceris® Tablet and Rectal Foam (budesonide) | 12/13/2017 |
| Varizig® (varicella zoster immune globulin) | 12/13/2017 |
| Varubi® (rolapitant) | 12/13/2017 |
| Venclexta™ (venetoclax) | 12/13/2017 |
| Verzenio™ (abemaciclib) | 12/13/2017 |
| Vimpat® (lacosamide) | 12/13/2017 |
| Xultophy® 100/3.6 (insulin degludec and liraglutide) | 12/13/2017 |
| Yescarta™ (axicabtagene ciloleucel) | 12/13/2017 |
| Yondelis® (trabectedin) | 12/13/2017 |
| Zilretta™ (triamcinolone acetonide extended-release injectable suspension) | 12/13/2017 |
| Zometa® (zoledronic acid) | 12/13/2017 |
| Zontivity® (vorapaxar) | 12/13/2017 |
| Mepsevii™ (vestronidase alfa-vjbk) | 12/7/2017 |
| Ophthalmic Prostaglandins | 12/7/2017 |
| Ophthalmic Prostaglandins | 12/7/2017 |
| Actimmune® (interferon gamma-1b) |
Click here to view the Humana Pharmacy Policy Updates »
Policy Alerts monitors Commercial and Medicare medical policies for changes. While Payers typically update medical policies annually, there are many reasons why a Payer might review or update a policy. When reviews occur out of cycle, they may go unnoticed. Policy Alerts keeps you informed of upcoming and unexpected coverage changes affecting your product. Quickly understanding the changes Payers make can help you adjust reimbursement strategies impacting your business.
Policy Alerts continuously monitors Commercial and Medicare Payer coverage information to keep you up-to-date on Payer decisions in real-time. Whenever changes occur, email notifications containing a summary of those changes are delivered to your inbox. Clients can access detailed coverage reports and medical policies on the interactive Dashboard portal. Save time and keep focused on the important Payer medical policy reviews and coverage decisions affecting your product!
Policy Alerts takes a client-focused hands-on approach and works hard to provide our customers with helpful insights and actionable analytics over raw data. We understand what our clients need and we are dedicated to making sure we provide timely, accurate and always up-to-date reports that can be used to implement and support a successful reimbursement strategy.
Health economic and reimbursement information provided by Policy Alerts is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules and policies. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice.
Related Posts
